| Literature DB >> 28281037 |
Tomoyuki Iwanaga1,2, Tsuyoshi Ushigami3, Kazushi Anzawa3, Takashi Mochizuki3.
Abstract
Tinea unguium caused by dermatophyte species are usually treated with oral antimycotic, terbinafine (TBF). To understand the mechanisms of improvement and recalcitrance of tinea unguium by oral TBF treatment, a method of quantifying dermatophyte viability in the nail was developed, and the viability of dermatophytes was analyzed in toenail lesions of 14 patients with KOH-positive tinea unguium treated with oral TBF 125 mg/day for up to 16 weeks. Mycological tests, including KOH examination and fungal culture, and targeted quantitative real-time PCR for internal transcribed spacer (ITS) region, including rRNA, were demonstrated at the initial visit and after 8 and 16 weeks of treatment. Assays in eight patients showed that average ITS DNA amount significantly decreased, to 44% at 8 weeks and 36% at 16 weeks compared with 100% at initial visit. No significant difference was observed between at 8 and 16 weeks, despite the TBF concentration in the nail supposedly more than 10-fold higher than the minimum fungicidal concentration for dermatophytes. This finding suggests the pathogenic dermatophytes in nail lesions could survive in a dormant form, such as arthroconidia, during oral TBF treatment. Both antimycotic activity and nail growth are important factors in treatment of tinea unguium.Entities:
Keywords: Dermatophyte; Onychomycosis; Quantitative real-time PCR; Terbinafine; Tinea unguium; Trichophyton; Viability
Mesh:
Substances:
Year: 2017 PMID: 28281037 PMCID: PMC5500682 DOI: 10.1007/s11046-017-0118-8
Source DB: PubMed Journal: Mycopathologia ISSN: 0301-486X Impact factor: 2.574
Primer sequences
| Primer | Sequence |
|---|---|
| ITSF | 5′-AGCCCGGCTTGTGTGATG-3′ |
| ITSR | 5′-CATTCGCCTAGGAAGCCG-3′ |
| ITS1 | 5′-TCCGTAGGTGAACCTGCGG-3′ |
| ITS4 | 5′-TCCTCCGCTTATTGATATGC-3′ |
Fig. 3The relative amount of ITS DNA before and after TBF treatment. Patients were treated with oral TBF for 16 weeks. The amount of ITS DNA in nail specimens was measured at 0, 8, and 16 weeks by qPCR and calculated relative to the initial visit (100%). Each bar represents the mean ± standard deviation (SD) of duplicate measurements from eight patients, with results analyzed statistically by one-way ANOVA with Tukey–Kramer multiple comparison tests. **p < 0.01
Demographic and clinical characteristics of the patients included in this study
| No. | Age (yr) | Gender | Region | Tinea pedis | Therapy | Assessment | First visit | Second visit 8 weeks | Third visit | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 60 | F | R1 | + | Terbinafine 125 mg/day | KOH | + | + | N. V. | |
| Culture | + | N. D. | ||||||||
| ITS DNA copy number | 7811 | 1788 | ||||||||
| 2 | 65 | M | L1 | + | Terbinafine 125 mg/day | KOH | + | + | + | |
| Culture | − | − | − | |||||||
| ITS DNA copy number | 18,486 | 9563 | 7244 | |||||||
| 3 | 76 | F | R1 | + | Terbinafine 125 mg/day | KOH | + | N. V. | N. V. | |
| Culture | − | |||||||||
| ITS DNA copy number | 2584 | |||||||||
| 4 | 64 | M | L1 | + | Terbinafine 125 mg/day | KOH | + | N. V. | N. V. | |
| Culture | − | |||||||||
| ITS DNA copy number | 9534 | |||||||||
| 5 | 75 | F | L1 | + | Terbinafine 125 mg/day | KOH | + | + | + | |
| Culture | − | − | − | |||||||
| ITS DNA copy number | 14,740 | 9038 | 6434 | |||||||
| 6 | 75 | M | L1 | + | Terbinafine 125 mg/day | KOH | + | N. V. | N. V. | |
| Culture | − | |||||||||
| ITS DNA copy number | 45,744 | |||||||||
| 7 | 59 | F | R1 | + | Terbinafine 125 mg/day | KOH | + | + | + | |
| Culture | − | − | N. D. | |||||||
| ITS DNA copy number | 14,373 | 8119 | 1851 | |||||||
| 8 | 66 | M | L1 | + | Terbinafine 125 mg/day | KOH | + | N. V. | N. V. | |
| Culture | N. D. | |||||||||
| ITS DNA copy number | 7597 | |||||||||
| 9 | 71 | M | L1 | + | Terbinafine 125 mg/day | KOH | + | + | + | |
| Culture | − | − | − | |||||||
| ITS DNA copy number | 47,652 | 25,928 | 38,434 | |||||||
| 10 | 73 | F | R1 | − | Terbinafine 125 mg/day | KOH | + | − | + | |
| Culture | − | − | − | |||||||
| ITS DNA copy number | 34,311 | 18,173 | 21,561 | |||||||
| 11 | 83 | F | R1 | + | Terbinafine 125 mg/day | KOH | + | + | N. D. | |
| Culture | − | − | N. D. | |||||||
| ITS DNA copy number | 636,527 | 155,854 | 16,097 | |||||||
| 12 | 73 | M | L1 | + | Terbinafine 125 mg/day | KOH | + | N. V. | N. V. | |
| Culture | + | |||||||||
| ITS DNA copy number | 2446 | |||||||||
| 13 | 59 | F | L1 | + | Terbinafine 125 mg/day | KOH | + | + | + | |
| Culture | + | − | − | |||||||
| ITS DNA copy number | 66,215 | 19,559 | 29,475 | |||||||
| 14 | 74 | F | L1 | + | Terbinafine 125 mg/day | KOH | + | N. V. | − | |
| Culture | + | − | ||||||||
| ITS DNA copy number | 4819 | 61 | ||||||||
| Summary | Average 69.5 | Ratio (M:F) 6:8 | Ratio (L:R) 9:5 | Rate of complications 93% | Positive rate | KOH | 100% | 88% | 86% | |
| Median 72 | DNA | 100% | 100% | 100% | ||||||
N.D. not determined; N.V. no visit